scholarly journals Etiological and pathogenetic aspects of diagnosis and treatment of viral hepatitides

2013 ◽  
Vol 94 (6) ◽  
pp. 785-792 ◽  
Author(s):  
V Kh Fazylov
Keyword(s):  
Hepatitis B ◽  
Viral Hepatitis ◽  
Antiviral Treatment ◽  
Antiviral Agents ◽  
Bacterial Overgrowth ◽  
Chronic Viral Hepatitis ◽  
Primary Hepatocellular Carcinoma ◽  
Treatment And Prevention ◽  
Metabolic Correction

The commencement address highlights the results of the long-term scientific research of the department of infectious diseases of the Kazan State Medical University on the problems of viral hepatitides diagnosis, treatment and prevention. The era of research of the acute viral hepatitides was based primarily on the clinical and biochemical differential diagnosis, considering epidemiologic data and specific prevention (vaccination) of hepatitis A and B. The development of modern technologies opened up new opportunities for etiologic decoding and morphologic evaluation of the infectious process activity in chronic viral hepatitis B, D and C. The results of hepatitis B and C genotyping, opening new opportunities for epidemiologic evaluation of their prevalence and antiviral treatment efficacy prediction, especially in family settings, are presented. A serious contribution is made to the study of latent HBV-infection, which is forming the long-term outcomes to cirrhosis and primary hepatocellular carcinoma. Pathogenetic connection of the systemic endotoxinemia, gastrointestinal bacterial overgrowth syndrome and immune dysfunction defined the morphologic and clinical and pathogenetic activity of the chronic viral hepatitis considering its molecular biologic verification. Contemporary diagnostics of chronic viral hepatitis (including HIV-coinfection) allowed to obtain the encouraging results in the development of the modern methods of antiviral (interferone, cytokines, nucle-os(t)ide analogs) and pathogenetic (metabolic correction - dimethyloxobuthylphosphonyldimethylate (dimephosphon), medical ozone, hepatoprotectors) treatment, in perspective - clinical use of direct antiviral agents (inhibitors of protease, polymerase etc.).

scholarly journals Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis

Scientifica ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-22 ◽  
Author(s):  
Peter Karayiannis
Keyword(s):  
Viral Hepatitis ◽  
Antiviral Agents ◽  
Standard Of Care ◽  
Pegylated Interferon ◽  
Chronic Viral Hepatitis ◽  
Future Perspectives ◽  
Direct Acting Antivirals ◽  
Current State ◽  
Direct Acting

The development and evaluation of antiviral agents through carefully designed clinical trials over the last 25 years have heralded a new dawn in the treatment of patients chronically infected with the hepatitis B and C viruses, but not so for the D virus (HBV, HCV, and HDV). The introduction of direct acting antivirals (DDAs) for the treatment of HBV carriers has permitted the long-term use of these compounds for the continuous suppression of viral replication, whilst in the case of HCV in combination with the standard of care [SOC, pegylated interferon (PegIFN), and ribavirin] sustained virological responses (SVRs) have been achieved with increasing frequency. Progress in the case of HDV has been slow and lacking in significant breakthroughs.This paper aims to summarise the current state of play in treatment approaches for chonic viral hepatitis patients and future perspectives.

1071 SHORT AND LONG TERM OUTCOME OF KIDNEY TRANSPLANTED PATIENTS WITH CHRONIC VIRAL HEPATITIS B AND C

2010 ◽  
Vol 52 ◽  
pp. S414
Author(s):  
E. Ridruejo ◽  
G. Soler Pujol ◽  
C. Díaz ◽  
M. Dávalos Michel ◽  
S. Marciano ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Viral Hepatitis B ◽  
Short And Long Term

scholarly journals Short and long term outcome of kidney transplanted patients with chronic viral hepatitis B and C

2010 ◽  
Vol 9 (3) ◽  
pp. 271-277 ◽  
Author(s):  
Ezequiel Ridruejo ◽  
Carlos Díaz ◽  
Mario Dávalos Michel ◽  
Gervasio Soler Pujol ◽  
Alfredo Martínez ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Viral Hepatitis B ◽  
Short And Long Term

Prophylaxis and treatment of chronic viral hepatitis as the prevention of hepatocellular carcinoma

2009 ◽  
Vol 150 (1) ◽  
pp. 19-26 ◽  
Author(s):  
Alajos Pár
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis B ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis

Mivel a hepatitis B- és C-vírus- (HBV-, HCV-) fertőzés döntő szerepet játszik a hepatocellularis carcinoma (HCC) keletkezésében, a HBV és HCV okozta hepatitis és cirrhosis megelőzése és kezelése egyben a HCC prevencióját is jelentheti. A HCC primer prevencióját képviseli a HBV elleni vakcináció és a donorok szűrése HBV- és HCV-markerekre. A szekunder prevencióhoz sorolható az interferonalapú és/vagy nukleozidanalóg anti-HBV- és anti-HCV-terápia, a cirrhosisos betegek HCC irányában történő alfa-foetoprotein + ultrahang szűrése, valamint a HCC kuratív reszekciója/ablatiója utáni adjuváns antivirális kezelés. Várható, hogy a HBV-vakcináció világszerte történő széles körű alkalmazása, továbbá az optimalizált individuális antivirális kezelésmódok, az új nukleozidanalógok és HCV-specifikus proteáz- és polimerázgátlók révén előrelépés történik nemcsak a vírushepatitisek megelőzésében és terápiájában, hanem a HCC prevenciójában is a nem túl távoli jövőben.

Viral Hepatitis Other than A, B, or C

2016 ◽  
Author(s):  
Nadeem Anwar ◽  
Kenneth E. Sherman
Keyword(s):  
Hepatitis B ◽  
Viral Hepatitis ◽  
Hepatitis E Virus ◽  
Hepatitis Virus ◽  
Cell Damage ◽  
Hepatitis E ◽  
Hepatitis D ◽  
Hepatitis D Virus ◽  
Treatment And Prevention ◽  
Key Words Hepatitis

Viral hepatitis is a global, although variably distributed, health problem associated with significant morbidity and mortality. Infection with a hepatitis virus leads to acute inflammation and liver cell damage (hepatocyte injury). Such infection may be symptomatic or subclinical and may result in disease resolution, death from fulminant hepatic failure, or development of  a chronic disease state. Whereas the chronic infection with hepatitis B and C accounts for a global burden of more than 500,000,000 cases, the global death rate from all types of hepatitis is approximately 1 million people annually. This review focuses on the virology, epidemiology, clinical features, diagnosis, treatment, and prevention of hepatitis D and hepatitis E, as well as other viruses associated with hepatitis. Figures show the global distribution of hepatitis D infection, elevation of anti–hepatitis D virus antibodies in hepatitis B/hepatitis D virus coinfection, geographic distribution of hepatitis E virus by genotype, factors significant in the pathogenesis of hepatitis E, and pattern of antibody elevation in hepatitis E. The table lists proposed diagnostic criteria for hepatitis E virus. This review contains 5 highly rendered figures, 1 table, and 42 references. Key words: hepatitis D, hepatitis D virus, hepatitis E, hepatitis E virus, non-A hepatitis, non-B hepatitis, non-C hepatitis, viral hepatitis 

Sign in / Sign up

Export Citation Format

Share Document